COVID-19 Quantitative Antibody Titers & Booster Vaccinations
Completed
Conditions studied: COVID-19, COVID-19 Vaccines, Immunogenicity, Vaccine
In brief
This is an observational study aiming at describing COVID-19 vaccination outcomes among HIV-positive and HIV-negative individuals, using electronic health records to observe their usual clinical care. This study will describe levels of COVID-19 vaccine response (i.e., Ig spike antibody measurements). Rates of antibody level decay after vaccination will be assessed. The efficacy of using antibody levels to help guide the timing of booster doses among HIV-negative and HIV-positive patients will be evaluated.
Key facts
- Study ID
- NCT05104359
- Run by
- Epividian
- People needed
- 825
- Starts
- 2020-12-11
- Expected to finish
- 2022-04-30
- Last updated by the study team
- 2022-07-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Cared for at AHF Midtown Manhattan Healthcare Center and followed in the OPERA observational database
- Active in care in the last 24 months
- Fully vaccinated against SARS-CoV-2 virus, implemented as 21 days after the second Pfizer or Moderna injections, 21 days after the one J\&J injection
- Received a Roche SARS-CoV-2 Semi-Quant Spike Ig AB test after full vaccination as usual clinical care
You may not qualify if…
- Unvaccinated or partially vaccinated against SARS-CoV-2 virus
- Never tested with a SARS-CoV-2 Semi-Quant Total AB test after full vaccination
Where it is running
- AHD Manhattan Midtown HCC — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.